Hemophilia Market Forecast 2024-2033: Projected CAGR, Key Drivers, And Trends|Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A

Overview and Scope
Hemophilia is a rare genetic disorder that affects the body’s ability to clot blood properly and generally occurs when a person gets injured and starts bleeding. Hemophilia treatment treats Hemophilia disease through various medical interventions and strategies to manage and address the bleeding tendencies associated with hemophilia.

Sizing and Forecast
The hemophilia market size has grown strongly in recent years. It will grow from $12.59 billion in 2023 to $13.83 billion in 2024 at a compound annual growth rate (CAGR) of 9.8%. The growth in the historic period can be attributed to government initiatives, increased number of hemophilic patients, rising diagnostic screening, increasing awareness about hemophilia treatments.

The hemophilia market size is expected to see strong growth in the next few years. It will grow to $19.4 billion in 2028 at a compound annual growth rate (CAGR) of 8.8%. The growth in the forecast period can be attributed to rising research and development hemophilias, rising diagnostic screening, incremental healthcare spending, global access to treatment. Major trends in the forecast period include new drug launches and approvals, escalation in novel drug development, research and clinical trials, digital health solutions, advancements in treatment options.

To access more details regarding this report, visit the link:
https://www.thebusinessresearchcompany.com/report/hemophilia-global-market-report

Segmentation & Regional Insights
The hemophilia market covered in this report is segmented –

1) By Type: Hemophilia A; Hemophilia B; Hemophilia C; Other Types
2) By Treatment: Replacement Therapy; Hemostatic Agents; Desmopressin; Gene Therapy; Other Treatments
3) By End-User: Hospitals; Clinics; Home Care Settings; Other End-Users

North America was the largest region in the hemophilia market in 2023. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in hemophilia market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

Intrigued to explore the contents? Secure your hands-on sample copy of the report:
https://www.thebusinessresearchcompany.com/sample.aspx?id=12905&type=smp

Major Driver Impacting Market Growth
The rising occurrence of genetic abnormalities is expected to propel the growth of the hemophilia market going forward. Genetic abnormalities, also known as genetic mutations or genetic disorders, refer to changes in the DNA sequence of an individual’s genes that can result in various health conditions and physical traits. Hemophilia treatment aims to prevent or control bleeding episodes, minimize complications and improve the quality of life for individuals with genetic abnormalities. For instance, in June 2023, according to Gene People, a UK-based registered charity organization that supports genetic conditions, one in every 25 kids had a genetic disorder. Consequently, 30,000 new-borns and young children in the UK and more than 2.4 million children and adults are affected by a genetic disorder each year. Therefore, the rising occurrence of genetic abnormalities is driving the growth of the hemophilia market.

Key Industry Players
Major players in the hemophilia market are Kedrion S.p.A., Chugai Pharmaceutical Co. Ltd., Pfizer Inc., F. Hoffmann-La Roche AG, Bayer AG, Sanofi S.A., Bristol-Myers Squibb Company, Takeda Pharmaceutical Company Limited, Novo Nordisk A/S, Baxter International Inc., CSL Limited, Biogen Inc., Grifols S.A., Octapharma AG, BioMarin Pharmaceutical Inc., GC Pharma, Alnylam Pharmaceuticals Inc., Bio Products Laboratory Ltd., Sangamo Therapeutics Inc., UniQure, Intellia tx, ProMetic BioSciences Ltd., Precision BioLogic Inc., Dimension Therapeutics, Chameleon Biosciences, Amarna therapeutics, HEMA Biologics LLC, Aptevo Therapeutics, Arcturus Therapeutics Inc., Ferring Lakemedel AB.

The hemophilia market report table of contents includes:

1. Executive Summary
2.Hemophilia  Market Characteristics
3. Hemophilia Market Trends And Strategies
4.Hemophilia  Market analysis
5.Hemophilia  Market Size And Growth
6.Hemophilia  Segmentation
7.Hemophilia  Regional And Country Analysis
.
.
.
27.Hemophilia  Competitive Landscape And Company Profiles
28.Hemophilia  Key Mergers And Acquisitions
29.Hemophilia  Future Outlook and Potential Analysis

TOP MAJOR PLAYERS:

• Kedrion S.p.A.
• Chugai Pharmaceutical Co. Ltd.
• Pfizer Inc.
• F. Hoffmann-La Roche AG
• Bayer AG
• Sanofi S.A

Explore the trending research reports from TBRC:

Contact Us:
The Business Research Company
Europe: +44 207 1930 708
Asia: +91 88972 63534
Americas: +1 315 623 0293

Email: info@tbrc.info

Follow Us On:
LinkedIn: https://in.linkedin.com/company/the-business-research-company
Twitter: https://twitter.com/tbrc_info
Facebook: https://www.facebook.com/TheBusinessResearchCompany
YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ
Blog: https://blog.tbrc.info/
Healthcare Blog: https://healthcareresearchreports.com/
Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model